VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
March 31, 2020 07:30 ET
|
VIVUS, Inc.
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk...
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
March 03, 2020 16:05 ET
|
VIVUS, Inc.
- Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported...
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
March 02, 2020 07:30 ET
|
VIVUS, Inc.
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif., March 02, 2020 (GLOBE...
VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
February 19, 2020 07:30 ET
|
VIVUS, Inc.
- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the...
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
February 18, 2020 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019...
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
February 05, 2020 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved...
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
January 07, 2020 07:30 ET
|
VIVUS, Inc.
-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- ...
VIVUS to Present at Biotech Showcase on January 13, 2020
January 02, 2020 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will present at...
VIVUS Adopts Stockholder Rights Plan
December 31, 2019 07:30 ET
|
VIVUS, Inc.
CAMPBELL, Calif., Dec. 31, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted...
VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
December 18, 2019 07:30 ET
|
VIVUS, Inc.
-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56...